ConductScience.org, home

Trial · NCT03100344

Participant flow12

How many started, completed or left each group, period by period.

PeriodMilestoneGroupParticipantsUnits counted
Overall StudySTARTEDPlacebo57
Overall StudySTARTEDNemolizumab (10 mg)55
Overall StudySTARTEDNemolizumab (30 mg)57
Overall StudySTARTEDNemolizumab (90 mg)57
Overall StudyCOMPLETEDPlacebo43
Overall StudyCOMPLETEDNemolizumab (10 mg)44
Overall StudyCOMPLETEDNemolizumab (30 mg)50
Overall StudyCOMPLETEDNemolizumab (90 mg)45
Overall StudyNOT COMPLETEDPlacebo14
Overall StudyNOT COMPLETEDNemolizumab (10 mg)11
Overall StudyNOT COMPLETEDNemolizumab (30 mg)7
Overall StudyNOT COMPLETEDNemolizumab (90 mg)12

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03100344/flow